Polycarbophil calcium

Identification

Name
Polycarbophil calcium
Accession Number
DB09311
Type
Small Molecule
Groups
Approved
Description

Polycarbophil calcium is a drug used as a stool stabilizer. Chemically, it is a synthetic polymer of polyacrylic acid cross-linked with divinyl glycol, with calcium as a counter-ion. Polycarbophil is used to treat constipation. This drug may also be used to help relieve the symptoms of irritable bowel syndrome or diarrhea. Less gas and bloating compared to psyllium laxative products, but can cause heartburn, and belly cramps. It is insoluble in water, dilute acids, and dilute alkali. The material possesses exceptionally high water-binding capacity. is not absorbed, does not interfere with the activity of digestive enzymes or intestinal absorption, possesses satisfactory stability, is physiologically inert, and does not cause gastrointestinal irritation.

Synonyms
  • Calcium Polycarbophil
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Calcium Polycarbophil 625 mgTablet625 mg/1OralRemedy Repack2016-10-06Not applicableUs
Calcium Polycarbophil 625 mgTablet625 mg/1OralReliable 1 Laboratories2015-11-01Not applicableUs
Care One FiberTablet, film coated625 mg/1OralAmerican Sales Company2004-03-30Not applicableUs
Equalactin - Tab 625mgTablet625 mgOralNumark Laboratories, Inc.1996-12-312009-07-31Canada
Equalactin LaxativeTablet625 mg/1OralNumark Brands, Inc1986-11-21Not applicableUs
Equate fiber therapyTablet, film coated625 mg/1OralWalmart Stores1996-11-052017-11-07Us
FiberTablet, film coated625 mg/1OralWestern Family Foods1998-01-19Not applicableUs
Fiber CapletsTablet625 mg/1OralMc Kesson2016-06-01Not applicableUs
Fiber CapsTablet, film coated625 mg/1OralGuardian Drug Company2010-07-15Not applicableUs
Fiber LaxTablet, film coated625 mg/1OralRugby2010-09-01Not applicableUs
International/Other Brands
Mitrolan
Categories
UNII
8F049NKY49
CAS number
126040-58-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Polycarbophil is used to treat constipation and to help maintain regular bowel movements.

Structured Indications
Not Available
Pharmacodynamics

Relieves constipation or diarrhea associated with bowel disorders and acute nonspecific diarrhea.

Mechanism of action

It is known as a bulk-forming laxative. It increases the bulk in the stool, an effect that helps to cause movement of the intestines. It also works by increasing the amount of water in the stool, making the stool softer and easier to pass.

Absorption

Calcium polycarbophil is not absorbed from the intestine.

Volume of distribution

Calcium polycarbophil is not absorbed from the intestine.

Protein binding

Calcium polycarbophil is not absorbed from the intestine.

Metabolism

Polycarrbophil calcium is not metabolized and has limited hydrophilic activity in acidic environments.

Route of elimination

Excreted in feces.

Half life

Calcium polycarbophil is not absorbed from the intestine.

Clearance

Calcium polycarbophil is not absorbed from the intestine.

Toxicity

The LD50 of calcium polycarbophil in young adult rats approximated 20 g/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Danhof IE: Pharmacology, toxicology, clinical efficacy, and adverse effects of calcium polycarbophil, an enteral hydrosorptive agent. Pharmacotherapy. 1982 Jan-Feb;2(1):18-28. [PubMed:6765389]
  2. Monograph [Link]
  3. webmd [Link]
External Links
KEGG Drug
D03306
PubChem Substance
347910435
Wikipedia
Polycarbophil_calcium
ATC Codes
A06AC08 — Polycarbophil calcium
AHFS Codes
  • 56:12.00 — Cathartics and Laxatives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingSupportive CareNarcolepsy1
Not AvailableCompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableTerminatedTreatmentColitis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral625 mg
TabletOral500 mg/1
TabletOral625 mg/1
CapsuleOral625 mg/1
Tablet, film coatedOral625 mg/1
TabletOral500 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Drug created on November 16, 2015 14:57 / Updated on November 19, 2017 20:34